source
- Latigo Biotherapeutics targets non-opioid pain market with $247 M IPOLatigo Biotherapeutics announced details of its planned initial public offering, aiming to raise roughly $247 million to advance its pipeline of non-opioid pain treatments. The company intends to…
- Lilly expands access to its experimental obesity therapy while Jazz pulls Zepzelca's second-line lung cancer useLilly announced it will broaden the expanded‑access program for its obesity drug that has not yet received regulatory approval, allowing more patients to receive the treatment under a compassionate…